- Home
- LNZA vs ECOR Comparison
LNZA vs ECOR Comparison
Compare LNZA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | ECOR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 39.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LNZA | ECOR |
|---|---|---|
| Price | $15.48 | $6.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.00 | ★ $25.50 |
| AVG Volume (30 Days) | 8.0K | ★ 57.9K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | $113.27 | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $11.20 | $4.16 |
| 52 Week High | $166.99 | $19.49 |
Technical Indicators
Market Signals| Indicator | LNZA | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 70.63 |
| Support Level | $13.50 | $4.65 |
| Resistance Level | $14.43 | $6.67 |
| Average True Range (ATR) | 0.63 | 0.39 |
| MACD | 0.29 | 0.19 |
| Stochastic Oscillator | 71.02 | 77.59 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.